ArticleNeurocritical care2026
Timing of Transfusion Strategy Initiation in Acute Brain Injury: A Subanalysis of the TRAIN Study.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRecent randomized trials suggested that a liberal transfusion strategy (LTS) may be beneficial compared with a restrictive strategy (RTS) in patients with acute brain injury (ABI), although results remain inconsistent across studies. The aim of our study was to investigate whether the time of initiation of these transfusion strategies might influence neurological outcomes in patients with ABI.
methodsThis was a post hoc exploratory analysis of the international, multicenter TRAIN randomized clinical trial. Adult patients with traumatic brain injury, aneurysmal subarachnoid hemorrhage, or intracerebral hemorrhage were randomized to receive transfusion at a hemoglobin threshold of either below 9 g/dL (LTS) or below 7 g/dL (RTS). The exposure of interest was time from intensive care unit (ICU) admission to randomization, analyzed both categorically (i.e., as early, ≤ 3 days vs. late, > 3 days) or as a continuous variable. The primary outcome was the occurrence of unfavorable neurological outcome at 180 days (UO), defined as a Glasgow Outcome Scale-Extended score of 1-5. Associations were examined using multivariable logistic regression, propensity score matching, generalized additive models, and segmented regression. A formal interaction between transfusion strategy and timing was tested to assess effect modification.
resultsAmong the 820 included patients, baseline characteristics were well balanced between transfusion strategies within early and late randomization groups. LTS was consistently associated with a lower probability of UO compared with RTS, both in early- and late-randomization group, although point estimates suggested a numerically stronger association when randomization occurred earlier [odds ratio (OR) 0.51, 95% confidence interval (CI) 0.34-0.76]. LTS was associated with fewer cerebral ischemic events (OR 0.33, 95% CI 0.14-0.77), shorter mechanical ventilation and ICU stay in the early-randomization group, whereas in the late-randomization group LTS was associated with lower rates of sepsis (OR 0.33, 95% CI 0.13-0.86) and ARDS (OR 0.39, 95% CI 0.2-0.78]). Continuous modeling showed no clear relationship between time to randomization and UO. The interaction between transfusion strategy and timing was not statistically significant (p = 0.88). Exploratory exposure-response analyses suggested that greater cumulative exposure to hemoglobin levels above 9 g/dL during the ICU stay was associated with a lower probability of UO.
conclusionsIn patients with ABI, a LTS was associated with a lower probability of unfavorable long-term neurological outcome across different times to randomization. Timing to randomization may influence the impact of transfusion strategies and the occurrence of some adverse events, although prospective studies specifically designed to address this question are needed to confirm it.
Indexed as
Identifiers
42806263What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.